The role of p21 3′UTR gene polymorphism in the risk of prostate cancer: A pilot study

Sivoňová, Monika Kmeťová; Vilčková, Marta; Jurečeková, Jana; Hatok, Jozef; Dobrota, Dušan; Dusenka, Robert; Kliment, J.

doi:10.3892/mmr.2012.1242

Cited by 5 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the present study found no significant association between this polymorphism and prostate cancer risk (OR=1.06; 95% CI, 0.72-1.58; P>0.05), as was also previously reported in our relatively small pilot study (47). Only one published case-control study evaluated the association of the p21 C70T polymorphic genotypes CT and TT with the risk of advanced prostate carcinoma in a European-American population (OR=2.24; 95% CI, 1.02-4.95) and these genotypes were more strongly associated with more aggressive metastatic disease (androgen-independent disease or fatality from metastatic prostate carcinoma) (48).…”

Section: Non-smokerscontrasting

confidence: 34%

Association of p53 and p21 polymorphisms with prostate cancer

Sivoňová¹,

Vilčková²,

Kliment³

et al. 2015

Biomedical Reports

Self Cite

View full text Add to dashboard Cite

Abstract. Cell cycle deregulation is common in human cancer. Alterations of the tumor-suppressor gene p53 and its downstream effector p21 have been indicated in the development of numerous human malignancies. Therefore, we hypothesize that the p53 codon 72 polymorphism, either on its own or in combination with p21 (C98A and C70T) polymorphisms, modifies the risk of prostate cancer within the Slovak population, and no previous studies have investigated these gene-gene interactions in the pathogenesis of prostate cancer in the Slovak population. Polymerase chain reaction-restriction fragment length polymorphism was used to determine the p53 and p21 genotypes in subjects comprising 300 prostate cancer patients and 446 healthy individuals. These 3 polymorphisms individually did not correlate with the prostate cancer risk. Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P<0.05] for subjects carrying the p53 codon 72 arginine (Arg)/proline (Pro)+Pro/Pro and p21 C98A CA genotypes compared to the combined reference genotypes p53 codon 72 Arg/Arg and p21 C98A CC. Neither the p53 genotypes nor the p21 genotypes showed statistically significant differences in Gleason score or serum prostate-specific antigen levels (P>0.05). A decreased risk of prostate cancer association with the p21 C98A CA genotype (OR=0.58; 95% CI, 0.36-0.93; P<0.05) in non-smokers compared to the non-smokers with the p21 C98A CC genotype was observed. Smokers carrying the p53 codon 72 Pro/Pro genotype were not at any significant risk of prostate cancer (OR=2.97; 95% CI, 0.51-17.15) compared to the non-smokers with the Arg/Arg genotype. Taken together, to the best of our knowledge this is the first study to show that a combination of the variant genotypes of p53 codon 72 and p21 C98A may modify the prostate cancer risk within the Slovak population.

show abstract

Section: Non-smokerscontrasting

confidence: 34%

Association of p53 and p21 polymorphisms with prostate cancer

Sivoňová¹,

Vilčková²,

Kliment³

et al. 2015

Biomedical Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…We failed to find associations with other cell cycle genetic susceptibility alleles which have been associated with risk of prostate cancer. Variants within CDKN1A have been found to be associated with risk of disease by both ourselves and others . We studied both of the variants previously implicated (rs1059234 and rs1801270) and failed to demonstrate an association.…”

Section: Discussionmentioning

confidence: 84%

Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In the current study, we observed no significant association between rs1059234 and rs1801270 polymorphisms of P21 gene and PTC risk. However, the association between these polymorphisms, risk of squamous cell carcinoma, 36 sporadic colorectal cancer, 37 cervical cancer, 34 prostate cancer, 38 uterine leiomyoma, 24 and Gastrointestinal Tract Tumor 39 has been reported previously. We also found no significant association between P21 polymorphisms (rs1059234 and rs1801270) and pathological and clinical characteristics of PTC.…”

Section: Discussionmentioning

confidence: 92%

The effect of TP53 and P21 gene polymorphisms on papillary thyroid carcinoma susceptibility and clinical/pathological features

et al. 2020

View full text Add to dashboard Cite

Papillary thyroid cancer (PTC) is the most common thyroid malignancy. Genetic polymorphisms of the TP53 and P21 genes are the candidate variants in various cancers development. This study investigated whether the polymorphisms in TP53 (rs1042522) and P21 (rs1059234 and rs1801270) affect the risk of PTC and whether such the genotype of these polymorphisms is associated with pathological and clinical characteristics of PTC. A case–control study was conducted with 286 Iranian people, including 131 PTC cases and 155 healthy controls. The genetic polymorphisms were investigated by the polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP). Our results suggested that TP53‐rs1042522 CC genotype was significantly associated with protection against PTC, in the dominant, recessive and allelic models (OR = 0.4, 95%CI: 0.2–0.8, P = .008; OR = 0.5, 95%CI: 0.3–0.9, P = .01; OR = 0.6, 95%CI: 0.4–0.8, P = .002, respectively). The rs1042522 was associated with PTC patients with tumor size greater than 1 cm in dominant and recessive models (OR = 0.2, 95%CI = 0.04–0.9, P = .04 and OR = 0.3, 95%CI = 0.1–0.7, P = .009, respectively) and was associated with vascular invasion in dominant model (OR = 0.3, 95%CI = 0.1–0.7, P = .01). No correlation was identified between P21 rs1059234 and rs1801270 polymorphisms and risk of PTC and pathological and clinical characteristics of PTC. Genetic variations in rs1042522 might alter the PTC risk, which could affect tumor size and cause lower incidence of vascular invasion in PTC cases. This was the first report suggesting that no correlation was found between P21 rs1059234 and rs1801270 polymorphisms and PTC risk. Thus, more studies with a larger population size and different ethnic groups and functional assays are needed to confirm our results.

show abstract

The role of p21 3′UTR gene polymorphism in the risk of prostate cancer: A pilot study

Cited by 5 publications

References 26 publications

Association of p53 and p21 polymorphisms with prostate cancer

Association of p53 and p21 polymorphisms with prostate cancer

Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma

The effect of TP53 and P21 gene polymorphisms on papillary thyroid carcinoma susceptibility and clinical/pathological features

Contact Info

Product

Resources

About